Abstract:Nonalcoholic fatty liver disease (NAFLD) is a serious disease. There are no specific drugs for it, in part because of the lack of effective models to aid drug development. However, it has been shown that three-dimensional organoid culture systems can reproduce the organ structure and maintain the gene expression profile of the original tissue. Therefore, we aimed to construct NAFLD models from liver organoids for pharmacological and mechanism studies. We successfully observed morphological changes in normal liver tissue in mouse liver organoids with positive albumin (ALB) expression and potential for differentiation toward hepatocyte-like cells. The mRNA expression of the hepatocyte markers ALB and hepatocyte nuclear factor 4 alpha increased after liver organoid differentiation. We observed free fatty acid (FFA)-induced lipid accumulation in organoids with significant increases in alanine aminotransferase, aspartate aminotransferase, total bilirubin, and triglyceride levels. Moreover, FFA-induced inflammatory cytokines (interleukin-6, tumor necrosis factor-α, and nitric oxide) and fibrosis indicators (collagen type I α1 and laminin α1) were also increased. In addition, RNA sequencing results showed that the expression of key genes [nucleotide oligomerization domain-like receptor (NLR) family apoptosis inhibitory protein, interferon regulatory factor (IRF) 3, and IRF7] involved in NAFLD metabolic abnormalities and insulin resistance in the NLR signaling pathway was altered after FFA induction of the liver organoids. Finally, we found that JC2-11 and lanifibranor limited the FFA-induced increase in oil-red lipid droplets, liver damage, inflammation, and liver fibrosis. In conclusion, tissue structure, gene expression, and the response of mouse liver organoids to drugs can partially mimic in vivo liver tissue. Liver organoids can successfully construct NAFLD models for drug discovery research.

Three-Dimensional Organoids as a Model to Study Nonalcoholic Fatty Liver Disease

Customized liver organoids as an advanced in vitro modeling and drug discovery platform for non-alcoholic fatty liver diseases

Mice Hepatic Organoids for Modeling Nonalcoholic Fatty Liver Disease and Drug Response

Modeling Human Nonalcoholic Fatty Liver Disease (NAFLD) with an Organoids-on-a-Chip System

A multicellular liver organoid model for investigating hepatitis C virus infection and nonalcoholic fatty liver disease progression

Human Multilineage 3D Spheroids as a Model of Liver Steatosis and Fibrosis

Generation of Fibrotic Liver Organoids Using Hepatocytes, Primary Liver Sinusoidal Endothelial Cells, Hepatic Stellate Cells, and Macrophages

Human Liver Organoid: Modeling Liver Steatosis and Beyond

A Novel 3d Liver Organoid System for Elucidation of Hepatic Glucose Metabolism

Liver Organoids: Established Tools for Disease Modeling and Drug Development

Human Hepatobiliary Organoids: Recent Advances in Drug Toxicity Verification and Drug Screening

Using Liver Organoids as Models to Study the Pathobiology of Rare Liver Diseases

Shedding light on non-alcoholic fatty liver disease: Pathogenesis, molecular mechanisms, models, and emerging therapeutics

Liver organoid as a 3D in vitro model for drug validation and toxicity assessment

Single-cell transcriptomics stratifies organoid models of metabolic dysfunction-associated steatotic liver disease

A 3D primary human cell-based in vitro model of non-alcoholic steatohepatitis for efficacy testing of clinical drug candidates

A decade of liver organoids: Advances in disease modeling

Development of alcoholic liver disease model for drug evaluation from human induced pluripotent stem cell derived liver organoids

Insight to Biofabrication of Liver Microtissues for Disease Modeling: Challenges and Opportunities

Modeling drug-induced liver injury and screening for anti-hepatofibrotic compounds using human PSC-derived organoids